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Sa greater number of synchronous lesions than the VATS
group (12% vs 7%, respectively). To explore further, we
also performed a separate analysis with synchronous pri-
mary tumors excluded and found the same pattern of recur-
rence. We hypothesized that if VATS missed synchronous
primary tumors at the time of initial lobectomy, then the
VATS group should demonstrate a greater number of meta-
chronous tumors over time. Surprisingly, the number of
metachronous lesions that developed in each group was
similar. Interestingly, the influence of synchronous primary
tumors as a potential confounder on outcome has not been
addressed in the vast majority of published VATS studies.
Based on the results of this study, the influence does not ap-
pear to be substantial because the presence of synchronous
primary tumors in the multivariate model was not signifi-
cant (odds ratio, 1.3; P ¼ .3).
The role of histology in non–small cell lung cancer has
been studied extensively. The vast majority of recent studies
demonstrate that cancer recurrences and cancer-related
deaths are somewhat greater in patients with adenocarci-
noma than other non–small cell histologies.19,20 The
VATS group in our study demonstrated a greater number
of patients with adenocarcinoma and a lower number of
patients with carcinoid tumor, which would appear to
favor the thoracotomy group. However, the results
demonstrated the contrary.
A major limitation of this study is selection bias. The
comparisons in this study are inextricably confounded by
the individual surgeon’s practice: 100% of the VATS lobec-
tomies are performed by 8 surgeons, whereas 2 surgeons
only perform thoracotomies. Thus unrecorded biases can-
not be separated from those related to the specific tech-
nique. Surgeon bias might have led to more synchronous
primary tumors in the thoracotomy group and more adeno-
carcinomas in the VATS group. The 2-month difference in
length of follow-up could result in a slight bias in favor of
the VATS group. There appears to be an immeasurable
factor or selection bias that consistently leads to improved
outcome in patients undergoing VATS observed with
many studies, or there might be a potential biological expla-
nation related to less trauma translating into an advantage.21
Thoracotomy is accepted as the gold standard in lung
cancer surgery. The pattern of recurrence demonstrated in
this study supports the argument that VATS lobectomy is
at least equivalent to the gold standard. However, no study
can replace clinical judgment at the time of the operation. In
situations in which oncologic principles might be compro-
mised, VATS should be converted to a thoracotomy. How-
ever, in appropriately selected patients VATS lobectomy is
an oncologically sound procedure.We thank Dr Rob McKenna for allowing Dr Raja Flores to ob-
serve his operative technique. Also, we thank Erlin Daley for her
editorial assistance.62 The Journal of Thoracic and Cardiovascular SurgeReferences
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Dr Scott Swanson (Boston, Mass). Raja, you and your col-
leagues are to be congratulated for a very nice study looking at
an important issue in lung cancer: that of recurrence following re-
section for early-stage disease. Your manuscript, which you kindly
provided me, is well written.ry c January 2011
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SYou and your colleagues had excellent outcomes with an ex-
tremely low operativemortality and a local recurrence rate of about
5%, which is similar to our published recurrence rate of about 3%.
Again, similar to your other papers for early clinical stage disease
was a finding of about 1/3 of patients being clinically understaged,
which reminds us all of the relatively low sensitivity of our radio-
logic imaging, evenwith the advent of expensive and relatively rou-
tine positron emission tomography scans. Also, you had about 10%
of patients with stage IIIA or IIIB disease. First question, can you
tell us how many patients had cervical mediastinoscopy?
Dr Flores. I don’t know howmany patients had cervical media-
stinoscopy.
Dr Swanson. Did any of the patients have that before their
lobectomy?
Dr Flores. If the positron emission tomography scan is positive,
the practice varies among surgeons. Some will do mediastino-
scopy, some will send the patients for induction chemotherapy,
and some will just resect and give chemotherapy afterward.
Dr Swanson.But of these 1100 clinical stage IA, did some have
a preresectional mediastinoscopy?
Dr Flores. I’m sure some. I think the number is relatively small.
This was all for clinical stage IA disease, so I’d have to say the
number is very, very small.
Dr Swanson.Okay. In the manuscript, you report that your data
was kept in a prospectively maintained database. Can you tell us
how this is prospectively maintained, what percentage of your
patients had follow-up, and do you use the Society of Thoracic
Surgeons database?
Dr Flores. We are members of the Society of Thoracic Sur-
geons database. This is prospectively maintained. Every Friday
morning, we have a conference where the attending is present,
we go over the staging, the attending gives their input as to what
was identified at the time of surgery, and this is recorded by a single
research assistant.
Dr Swanson.A number of patients were found to have synchro-
nous primaries—about 10%. Were these suspected based on the
preoperative computed tomography or were they complete sur-
prises?
Dr Flores. That’s a difficult question to answer. I think it’s
a very good question and something that I tried to look into.
From the database, it’s difficult to tell how many of these were
planned and how many of these were incidentally found. The ma-
jority of them were less than a centimeter. Most likely they were
incidentally found. I can’t ascertain that from the database.
Dr Swanson. Finally, most striking about this paper is the sta-
tistically significant decrease in overall recurrence for video-assis-
ted thoracoscopic surgery (VATS) versus open lobectomy,
particularly because the stage distribution was the same and,
more importantly, the size was identical between the 2 groups—
2.1 cm—and there were more adenocarcinomas in the VATS
group. This mirrors the findings of a large meta-analysis by the
Minnesota group that I was involved with and published in the An-
nals of Thoracic Surgery last year. What do you make of this, and
do you think this is related to the concept of less operative trauma
and suppression of the immune system? With such a striking re-
sult, about a 6% difference, which would buy somebody adjuvant
chemotherapy, do you think patients should be recommended to
have a VATS procedure for oncologic reasons?The Journal of Thoracic and CExcellent work, Raja, and I appreciated the chance to comment
on the paper.
Dr Flores. Thank you.
I think whenever it comes to recommending a surgical proce-
dure because of biologic reasons, and many have published on
that, about decreased cytokines, interleukins, that could have a fa-
vorable oncologic outcome on the patient, I think we have to be
careful about jumping to conclusions with that. I am still not con-
vinced based on the nature of this study that there is not a selection
bias going on, which is immeasurable. We did not anticipate hav-
ing a higher number of synchronous primaries in the thoracotomy
group. Of course, after further investigation, we identified that.
That is also something that I think many of the previous VATS pa-
pers don’t comment on. So I’m sure that there is some selection
bias taking place that favors the VATS patients. I just can’t figure
it out. I hope there is a potential to figure out some underlying bi-
ologic advantage from less trauma, but I don’t think I would make
that statement based on this data.
Dr Bryan Meyers (St. Louis, Mo). You can eliminate the pos-
sibility of a selection bias by doing some sort of a propensity
matching. That might be a help. You can also discuss briefly the
possibility of a detection bias; if only 2 surgeons were doing the
thoracotomy and 8 were doing the VATS, do they have a different
protocol for following these patients up that might have led to a dif-
ference? And then the other thing which was interesting, kind of
a coincidence, when we were quizzing Bob Timmerman at the
General Thoracic Surgical Club about the low rate of recurrence
after stereotactic radiation therapy, based on what we know exists
if you do a lymph node dissection in N1 and N2 stations in clinical
stage I lung cancer, there was a suggestion or hint that maybe the
decreased hit on the immune system that stereotactic radiation
therapy has helps reduce the chances of recurrence over VATS lo-
bectomy. So, if you think VATS lobectomy is better because it’s
less invasive, then you might have to take the next step.
Dr Flores.Well, as a thoracic surgeon, I refuse to accept that. I
think the good question is the propensity score. I investigated
whether we should do propensity score analysis on this paper or
not. We did it on our last paper. I think when you have a cohort
that is as well balanced as this, it may actually make it worse,
and it did make it worse on our last paper. Propensity score anal-
yses are best when it’s performed on thousands of patients. When
you have hundreds of patients, such as this, I can argue that it may
not be as good, and it throws out a lot of useful data when you nar-
row down your cohort to that extent.
Dr Mark Krasna (Baltimore, Md). Great paper, Raja. Because
you have such a very good cohort in the 7-year time frame, you
have another unique opportunity related to what Dr Meyers hinted
to, and that is follow-up. So, can you tell us what the current rou-
tine follow-up is at Sloan for your patients during that 7-year pe-
riod? One of the very interesting things that you found was no
specific difference in your metachronous lesions. You did talk
about a difference in distant failure, but it would actually be
very interesting to see was there a difference in terms of the meta-
chronous lesions with VATS lobe versus open. So did you follow
the same follow-up routine for all 8 surgeons over the 7 years?
Dr Flores. All surgeons follow-up patients the same way. I’m
sorry, Bryan, I forgot to address that.
Dr Krasna. So what is that algorithm?ardiovascular Surgery c Volume 141, Number 1 63
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SDr Flores. Basically, computerized axial tomography scans af-
ter surgery every 6 months.
Dr Krasna. For how many years?
DrFlores. I followmypatients forever. I thinkmost of the attend-
ings will get computerized axial tomography scans once a year. It’s
every 6 months, and then when you hit 5 years, once a year.
Dr Cerfolio. You follow every patient forever? God bless you.
Dr Thomas D’Amico (Durham, NC). Raja, you explained that
therewere 8 surgeons that did VATS, 2 that didn’t, and yet less than
50% of the total clinical stage IA were VATS. You would have
thought it would be 80%. So there had to be some selection.
How did it get to be less than 50%? That’s the first question.
And how did you analyze your conversions?
Dr Flores.Well, the majority of surgeons who do the bulk of the
cases, the VATS cases and the open cases, have bigger practices
than the younger guys who are just starting, so that’s where the ma-
jority of cases come from. As far as conversions, this is something
that I have labored over with this study, and that’s a point that I al-
ways bring up, and in our last paper that was one of the center
points: What do you do with the conversions. In my last paper,
because survival was the primary endpoint, I included them in
an intent-to-treat analysis in the VATS group. In this study recur-
rence rate is the primary endpoint. I included those in the thoracot-
omy group for a variety of reasons, including consultation with 6
biostatisticians to be sure that that was appropriate for this study.
So that’s usually my question. For this study, because the gold stan-
dard is thoracotomy and because of the lack of bimanual palpation
in the VATS group, we thought that it was better to analyze this
group in the thoracotomy group.
Dr SandroMattioli (Bologna, Italy). First, what kind of thora-
cotomy did you do? Second, did you consider the position of the
small nodule?64 The Journal of Thoracic and Cardiovascular SurgeDr Flores.We looked at the location of the nodule, you know, in
the upper, lower, middle lobe. We didn’t look specifically within
that lobe. The thoracotomy was usually a serratus-sparing thora-
cotomy, fifth interspace, and a Finochietto retractor was used in
the majority of cases.
Dr Joseph Shrager (Stanford, Calif). You didn’t emphasize it
in your presentation, but in the abstract you emphasized that the
synchronous primary rate would be much higher at thoracotomy.
However, I would argue that that’s basically not relevant because
presumably the patients that have a suspected synchronous pri-
mary, a little 5-mm ground-glass opacity or something, on the pre-
operative scan, are most often going to get a thoracotomy, unless
it’s clearly accessible to VATS—very peripheral.
Dr Flores. I’m not sure if I agree with that. I’ve tried to figure
out how to explain this, and there is no way of knowing ahead of
time. When you look at Cerfolio’s paper, and that actually promp-
ted me to perform this, the number of malignancies that he de-
scribed in his paper was 8.4%. Ours is 7%. Our thoracotomy
group was 11%. I think it’s tough to tell what we’re doing before
we get to the operating room based on what’s recorded in the
database.
Dr Shrager. I suspect that most people who do these opera-
tions both ways will tend to do an open operation if, in terms of
second lesions, there’s anything more than one very peripheral
one.
Dr Flores.Notme. If there are 2 lesions there, I’ll go ahead with
the lobectomy for the larger lesion and I’ll wedge or segment out
the second lesion.
Dr Shrager. You can’t always find a 5-mm ground-glass lesion
with your finger at VATS—unless it’s very peripheral.
Dr Flores. Most of the time with digital palpation, I’ll argue
that we can.ry c January 2011
